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Objectives: Smoking in diabetics is associated with a worse prognosis and vascular 
complications. The available evidence on health care resources utilization and associ-
ated costs in diabetics who smoke is limited or nonexistent. Thus, the objective was 
to compare health care resource utilization and costs according to smoking status in 
patients with type 2 diabetes in clinical practice. MethOds: A retrospective cohort 
nested case-control study was designed. Cases were current smokers, while two types 
of controls (former smokers and never smokers) were matched, two controls per 
case, for age, sex, duration of diabetes, and burden of comorbidity using data from 
electronic medical records. Non-institutionalized diabetics, both genders, age > 18 
years, seen consecutively over a 5-year period before the index date were enrolled. 
Perspective of both the National Health System and the Society were chosen and costs 
of health care resource utilization and loss of productivity due to sick leaves were 
compared among groups using a linear general model with covariates. Results: A 
total of 2,490 records were analyzed: 498 from cases, 996 from former smokers, and 
996 from never smokers. Mean age was 63.4 years (64.9% male). Smokers had higher 
HbA1c (7.4% vs. 7.2% and 7.2%, respectively, p = 0.013) and a lower degree of metabolic 
control (49.2 % vs. 54.7% and 55.8%, p = 0.036). Smokers had higher average annual 
costs (€ 3,583) than former smokers (€ 2,885) and never smokers (€ 2,183), p< 0.001. Mean 
annual health care cost saving per patient was associated with elapsed time of quit-
ting smoking from € 950 in subjects quitting smoking 2-year to € 1173 5-year or more, 
p< 0.05. cOnclusiOns: Diabetic smoker patients had lower metabolic control, higher 
health resource utilization, and more sick leave, resulting in higher health care costs 
and lost productivity compared with both former and never diabetic smokers. Health 
care cost-savings was associated with elapsed time from quitting smoking.
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Objectives: The aim of this analysis was to estimate the potential GH waste per 
patient with pen devices and the easypod® device, and to quantify the potential 
economic impact of expected GH waste from patient and health care organization 
perspectives. MethOds: A Waste Calculator Model was developed to examine GH 
waste. All somatropin products available in pen or electronic devices were included. 
The user may define distribution across cartridges sizes. The mechanical/priming 
loss applied to each product was based upon each product’s prescribing information 
and/or instructions for use. The base case model utilizes a US patient daily dose of 1.4 
mg. The model assumes that the easypod® dose adjustment feature is activated by 
the clinician (±25%). Model assumes that 42.6% of caregivers discard the remaining 
amount left in the cartridge (eg waste) if less than a full dose. Annual amount of GH 
waste (mg, cartridges, dollars) per patient and per population (based on US national 
market shares) for each pen/device is reported. Results: The expected annual 
amount of waste per patient was lowest for easypod®. The expected annual amount 
of waste per patient was highest for Omnitrope®. The expected annual amount of 
waste ranged from 0 to 38.9mg per patient per year, which is equal to 0 to 8 cartridges 
per patient per year and/or 0 to $2,935 per patient per year. For a patient population 
of 100 GH-treated patients, the annual amount of waste is estimated at 2,009 mg, 
which can be translated into approximately 342 cartridges or about $162,000 per year. 
The results in GH waste fluctuated depending upon daily dose, cartridge size, and 
dose spread assumptions. cOnclusiOns: The expected annual amount of GH waste 
evaluated in this Waste Calculator was lowest with easypod®. Cost of GH waste can 
be an important consideration when evaluating GH delivery devices.
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Objectives: It is estimated that the prevalence of moderate-to-severe SA (apnoea-
hypopnoea index > 15/h) is 10%. Patients with T2DM have a particularly high inci-
dence of SA. T2DM and SA influence the development and progression of each 
other. This study investigated the effects of PAP therapy in SA patients with T2DM 
on all-cause mortality and cost of illness (COI) in Germany from a statutory health 
insurance (SHI) perspective. MethOds: A total of > 4 million individuals covered by 
the SHI database were analysed (≈5% of the German SHI population). PAP therapy 
was initiated in 4,068 patients with SA (PAP group). Propensity score matching 
was used to define a control group (CG) of 4,068 SA patients matched for age, sex, 
risk factors/aetiology, region and medication who received usual care (no PAP). Of 
these, 1,280 patients in the PAP group and 1,186 patients in the CG had comorbid 
T2DM. This subgroup of patients was followed for 3 years after initiation of PAP 
therapy. Results: Total COI was higher in the PAP group versus CG in year 1 (€ 8,105 
vs € 7,037, p< 0.0001). After 2 years’ follow-up, COI in the PAP group decreased but 
remained higher versus CG (€ 6,842 vs € 6,625, p< 0.001). After 3 years, PAP group COI 
associated with manually coded meters (model 1 and model 2) and autocoded meters 
(model 3). Cost data was based on median prices for medicines, devices, medical 
services in National health care system in the Russian Federation. Results: Annual 
direct costs per patient in the group of manually coded glucose meters were 1533 euro 
(model 1) and 1574 euro (model 2), and in the group of autocoded meters were 1557 
euro (model 3). Annual total costs per patient in the group of manually coded glucose 
meters were 2992 euro (model 1) and 2921 euro (model 2), and in the group of auto-
coded meters were 3034 euro (model 3). Cost-effectiveness ratio for autocoded meters 
was 1875 euro (model 3) and for manually coded meters was 1954 euro (model 1) and 
1982 euro (model 2) per 1 LYG, respectively (discounted at 3%). Budget impact analysis 
showed that use of autocoded meters (model 3) instead of manually coded (model 
1 and model 2) leads to the annually cost savings of 33 euro and 53 euro per patient, 
respectively (discounted at 3%). cOnclusiOns: Obtained results approve the use of 
autocoded blood glucose meters instead of manually coded blood glucose meters to 
administrate blood glucose level as part of intensive glucose-lowering therapy from 
a pharmacoeconomic point of view.
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Objectives: The costs of obesity are staggering, accounting for 2-6% of global 
health care costs. The health economic benefits of bariatric surgery while notable, 
are multi-faceted, resulting in heterogeneous reporting in the literature. To that 
end, this study seeks to 1) highlight available evidence of the health economic 
impact of bariatric surgery, and to 2) identify key gaps in current evidence that 
may influence uptake by health care systems. MethOds: Evidence of the health 
economic impact was collated from 107 scientific articles, of which 19 were sys-
tematic reviews, published between 2010-March 2014 and archived in MEDLINE and 
PubMed. Additionally, HTAWatch identified 10 HTAs, largely from North America 
and the EU that evaluated economic benefits. Results: In all countries where 
evaluated, bariatric surgery was cost-effective compared to non-surgical therapy. 
The surgery was likely more cost-effective with higher patient BMI and with comor-
bidities, especially for BMI> 40kg/m2, although estimates varied. Furthermore, 
resolution of underlying comorbidities resulted in reduced utilization of health 
care services, pharmaceutical utilization, and improved work productivity, among 
others, resulting in cost saving of 60-70% relative to standard care over a 3-year 
period. Importantly, time to break even was typically in the 4-7 years range, and 
was shorter for patients with Type 2 Diabetes Mellitus (T2DM) and with BMI> 40kg/
m2, typically in the 1.25-5 year range. Three key evidence gaps were identified: few 
studies computed long-term cost-effectiveness; no head-to-head trials have directly 
compared different surgical procedures; and heterogeneity across populations and 
health system impede meta-analyses of patient outcomes such as QoL and long-
term health benefits. cOnclusiOns: Although heterogeneous, reports of health 
economic benefits of bariatric surgery indicate an overall positive trend, largely 
via reduction of health resource utilization. To firmly establish its impact, future 
studies need to conduct head-to-head comparisons, determine optimal patient 
populations, and employ standard clinical endpoints to demonstrate real world, 
long-term benefits.
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Objectives: Type 2-diabetes and excess weight incur large costs to health care 
systems, but the association between weight progression in diabetes and health 
care costs is unknown. We investigated those relations using real world data 
in a sample of newly diagnosed diabetes patients in Sweden by using repeated 
body mass index (BMI) measurement and health care resource utilization 
data MethOds: Patients with a BMI (kg/m2) measure at diagnosis and subsequent 
BMI measures at 12,24,36,48, and 60 months were identified from a previously 
conducted register study. Individuals were classified into three groups based on 
their BMI change over 5 years: increase (> 1 BMI unit increase), decrease (> 1 BMI 
unit decrease), and stable (≤ 1 BMI unit change). Each group was stratified by BMI 
at diagnosis (BMI 18-25; 25-30; ≥ 30). Health care costs for each group were esti-
mated by applying Swedish unit costs to the health care resource data extracted 
from electronic patient journals and a national patient register. Results: The 
study included 903 T2D patients (women, 43%; mean age, 62; mean HbA1c, 6.78%; 
mean BMI, 30.9). The BMI increased, decreased, or remained stable in 178 (20%), 
387 (43%), and 338 (37%) patients, respectively. Among patients with baseline BMI 
18-25 (n= 104), the five year cumulative health care costs were € 13,695, € 9,059, 
€ 8,936, in the increase, decrease, and stable group, respectively. Corresponding 
figures were € 11,470, € 7,950, € 8,683 for patients with baseline BMI 25-30 (n= 321), 
€ 14,387, € 9,465, and € 9,302 for patients with BMI ≥ 30 (n= 478). cOnclusiOns: In 
newly diagnosed diabetes, an increase in BMI lead to increased health care costs, 
irrespective of baseline BMI. Linking registry data on repeated BMI measurements 
and health care utilization is a valuable approach to investigate the association 
between weight changes and costs. Costs of interventions that maintain weight 
in patients with diabetes should be considered in the context of costs associated 
with weight gain.
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22700 diabetic patients in Madrid was used to estimate transition probabilities in 
the model. Time horizon was 10 years. Prices were taken from the health care tariffs 
published by the Regional Health Service in Madrid and from Spanish literature. They 
were updated to 2013 price levels and adjusted to subsequent years by a 3% infla-
tion rate. We used the perspective of the Regional Health Service in Madrid (public 
payer). Results: The model included an acute event and 3 health states. The increase 
in total costs in 10 years was € 1,328 per DM patient (133 € per year). In patients 
with hypertension the costs increased by 1,519€ in 10 years (152 € ); whereas the 
total increase in costs in patients with obesity was 1,535 € (153 € ). cOnclusiOns: 
IS has a relevant impact on the costs of management of DM. Hypertension and 
obesity increase these costs even further. Prevention of DM complications and an 
adequate control of risk factors can lead to cost savings for the management of DM. 
Understanding future costs of DM might be valuable for economic evaluations.
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bAckgROund: High prevalence and chronic complications are key determinants 
of management costs of Diabetes Mellitus (DM). Given that DM affects more than 4 
million people in Spain, the costs associated with this disease require an efficient 
management. Cardiovascular diseases are complications associated with DM with 
a major impact in health care budgets. Objectives: Develop a model to predict 
future costs of DM in Spain. Estimate the increase in health care costs in DM patients 
associated with potential cardiovascular diseases. We used the perspective of the 
Regional Health Service in Madrid (public payer). MethOds: Foro Gerendia is an 
initiative constituted by health care professional, experts in DM management. A 
Markov model for DM was developed based on the opinion of Foro Gerendia and on 
previous works in this area. A 5-year primary care data registry of 22700 diabetic 
patients in Madrid was used to estimate transition probabilities in the model. Time 
horizon was 10 years. Prices were taken from the health care tariffs published by the 
Regional Health Service in Madrid and from Spanish literature. They were updated to 
2013 price levels and adjusted to subsequent years by a 3% inflation rate. Results: 
Cardiovascular complications included in the model were ischemic heart diseases 
(acute myocardial infarction and angina) and heart failure with a total of 5 health 
states. The estimated increase in costs was € 1,080 per patient in 10 years (€ 108 
per year). Considering an 8% prevalence of DM in Madrid, the increase in costs of 
DM due to cardiovascular diseases would be € 52 million per year. cOnclusiOns: 
Cardiovascular diseases in DM patients have a relevant impact on health care 
expenditure. Prevention of cardiovascular complications can lead to significant 
cost savings for the management of DM. Understanding future costs of DM might 
be valuable in terms of budget allocation and economic evaluation.
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Objectives: Hypercholesterolemia is a risk factor for ciculatory diseases. This study 
estimates the impact of hypercholesterolemia on populations’ health levels and its 
economic impact in Portugal. MethOds: The impact on health status is measured 
by the loss of life years adjusted for disability (DALYs - Disability Adjusted Life Years). 
The economic impact analysis includes two components. The first estimates the 
direct costs generated by hypercholesterolemia including consumption of health 
care, social support, and other associated costs (e. g. transport). The second esti-
mates indirect costs, those related to the losses of productivity. The disease burden 
and the costs of illness attributable to hypercholesterolemia include also the com-
plications attributable to this risk factor, namely ischemic stroke and ischemic heart 
disease. In order to estimate the attributable fractions to hypercholesterolemia (total 
cholesterol ≥ 200mg/dL or statin use) of the diseases considered, a microsimulation 
approach was employed by using Framingham equations on the national database 
(VALSIM). In a counterfactual scenario hypercholesterolemia was eliminated from 
these observations and the resulting proportional change in the probability of CV 
events was taken as the hypercholesterolemia attributable fractions. These frac-
tions were used to estimate the contribution of hypercholesterolemia to the burden 
and the annual costs of the aforementioned circulatory diseases. Results: 1,689 
deaths can be attributed to hypercholesterolemia, which corresponds to 1.6% of the 
total deaths in Portugal in 2010. The DALYs resulting from disability and premature 
deaths caused by hypercholesterolemia in 2010 totaled 12,174. The estimated direct 
cost attributable to hypercholesterolemia in 2013 prices is € 320 million (€ 32 million 
for in-patient care and € 288 million for ambulatory care). Indirect costs generated by 
disability attributable to hypercholesterolemia add up to € 198 million. The overall 
costs of disease are therefore estimated at € 518 million, about 0.3% of Portuguese 
GDP. cOnclusiOns: In Portugal, we observed substantial burden and costs associ-
ated with Hypercholesterolemia.
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was significantly reduced versus CG (€ 6,798 vs € 6,954, p< 0.001). PAP recipients had 
a significantly lower 3-year mortality rate versus CG (7.2% vs 10.9%, p< 0.008; rela-
tive risk reduction 33.8%). cOnclusiOns: SA patients with T2DM treated with PAP 
showed significantly reduced mortality and morbidity. Total COI was higher in PAP 
recipients versus CG in the first two years of follow-up, but during year 3 COI was 
significantly lower in the PAP group versus CG. In addition to the known advantages 
of PAP therapy in SA patients with T2DM (e. g. improved glycaemic control), PAP 
therapy may be beneficial from an economic perspective.
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Objectives: To determine differences in total health care expenditures among 
general diabetics and newly diagnosed diabetics before and after HbA1c was 
implemented as the standard diagnostic factor. MethOds: Medical Expenditure 
Panel Survey-Household component 2009 and 2011 databases were used. Annual 
health care expenditures formed the dependent variable. Demographic factors, 
comorbidities, prescription drug costs, medical events and utilization variables for 
health care services like visits to office-based, outpatient and inpatient facilities, 
emergency rooms, home health care for 2009 and 2011 formed the independent 
variables. Patients diagnosed within the 2009 and 2011 years, were categorized into 
a dichotomous new diagnosis variable. General linear regression was conducted 
to compare predictors of total diabetes health care expenditures in 2009 and 
2011. Results: The mean total health care expenditure decreased in 2011 com-
pared to 2009 among general diabetics {$10,901 (95%CI= $9,013-$11,836) vs $11,458 
(95%CI= $10,715-$12,201)} and the newly diagnosed ones {$9,462 (95%CI= $6201-
$12,721) vs $8,429 (95%CI= $6793- $10,064)}. Among general diabetics in 2009, total 
expenditures showed significant relationships with prescription drugs, emergency 
room, home health care, outpatient facility and physician services expenses (all 
values p< 0.0001). The 2011 model was similar, but included associations between 
office-based provider visits (p< 0.0001) and previous incidences of heart attacks 
(p= 0.008). In 2009, among newly diagnosed patients, total expenditures were 
significantly associated with home health facilities expenditure (p< 0.0001) as 
opposed to no association in 2011. In both years, prescription medication, emer-
gency room and hospital inpatient facilities expenses contributed to spending. 
Visits to office-based and outpatient department providers, number of home-
health provider days (all values p< 0.0001) and hospital discharges (p= 0.0011) 
impacted total expenditures in 2009 and 2011 respectively. cOnclusiOns: Due 
to the many variables significantly affecting diabetes health expenditures, reduc-
tion in costs could not be solely attributed to the implementation of the HbA1c 
diagnostic criteria. Further research on cost-effectiveness of the HbA1c factor is 
warranted to establish any possible association.
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Objectives: The aim of this study was to assess the direct costs of ambulatory 
treatment associated with types 1 and 2 diabetes mellitus (DM) from the public 
payer perspective in Poland, and to explore the relative contribution of different cost 
components in the total direct cost of DM. MethOds: The estimates were based 
on reimbursement data from the years 2012 and 2013 provided by the public payer 
in Poland. Reimbursement costs of insulin, oral anti-diabetes drugs and monitoring 
strips were taken into account. Costs were presented in Polish zloty (PLN). Results: 
Total reimbursement costs for the public payer of anti-diabetes treatment were 1.3 
billion PLN in 2012 and 1.5 billion PLN in 2013, representing 19% and 21% of the 
total Polish reimbursement expenditures in 2012 and 2013, respectively. The highest 
component of anti-diabetes treatment costs was monitoring strips (645 million PLN 
in 2012 and 793 million PLN in 2013, 49% and 52%, respectively). Insulin costs (518 
million PLN in 2012 and 583 million PLN in 2013) and anti-diabetes oral drug costs 
(144 million PLN in 2012 and 155 million PLN in 2013) constitute 38-40% and 10-11% 
of total reimbursement costs, respectively. Regarding insulin, human insulin had a 
larger share of the costs (60-62%) than insulin analogs (38-40%). Premixed human 
insulin (65-66% reimbursement costs) and premixed insulin analogs (47-52% reim-
bursement costs) represent the largest share of the reimbursement costs of human 
insulin and insulin analogs, respectively. Reimbursement costs of biguanides and 
sulphonylureas represent 49-54% and 40-44% of total reimbursement costs of oral 
anti-diabetes drugs, respectively. cOnclusiOns: Total direct costs of diabetes mel-
litus treatment constitute a major part of reimbursement expenditures in Poland 
and are still growing. The main cost driver was reimbursement of monitoring strips, 
and the costs of insulin reimbursement were slightly lower.
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bAckgROund: Diabetes (DM) has a relevant impact on health care budgets mainly 
due to its high prevalence and its chronic and acute complications. Isquemic stroke 
(IS) is one of the macrovascular complications associated with DM and its incidence 
increases with the presence of some risk factors such as hypertension and obe-
sity. Objectives: Develop a model to predict future costs of DM in Spain. Estimate the 
increase in health care costs associated with potential IS in DM patients. MethOds: 
Foro Gerendia is an initiative constituted by health care professional, experts in DM 
management. A Markov model for DM was developed based on the opinion of Foro 
Gerendia and on previous works in this area. A 5-year primary care data registry of 
